Latest Articles

Publication Date
Fluorescence-Guided Bladder and Ureter Visualization in Benign Robotic Gynecologic Surgery: A Series of Five Cases.

Indocyanine green (ICG) near-infrared fluorescence imaging is well established in gynecologic oncology, but its role in benign minimally invasive surgery is still limited and not standardized. Increasing cesarean section and …

Published: Dec. 9, 2025, midnight
AI-Driven Advances in Women's Health Diagnostics: Current Applications and Future Directions.

Background: Women's health has historically served as an incubator for major medical innovations yet often faces relative neglect in sustained funding and implementation. The rise of artificial intelligence (AI) and …

Published: Dec. 3, 2025, midnight
Oncology Nurse Turns Pain Into Purpose As End Endo 5K Leader - Endometriosis Foundation of America

Oncology Nurse Turns Pain Into Purpose As End Endo 5K Leader Endometriosis Foundation of America

Published: Nov. 25, 2025, 6:57 p.m.
Oncology Nurse Who Had Stage IV Endometriosis and a Hysterectomy at 25 Leads End Endo 5K Participants to New Record - Endometriosis Foundation of America

Oncology Nurse Who Had Stage IV Endometriosis and a Hysterectomy at 25 Leads End Endo 5K Participants to New Record Endometriosis Foundation of America

Published: Nov. 25, 2025, 6:57 p.m.
Massive serous cystadenofibroma with incidental umbilical endometriosis in a morbidly obese patient presenting as acute respiratory compromise.

We present a case of a woman in her 50s with a rapidly expanding giant serous cystadenofibroma of the ovary. The 40-kg mass displaced her bowel and splinted her diaphragm, …

Published: Nov. 24, 2025, midnight
This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data - CancerNetwork

This Week in Oncology: FDA Approval Shakeups and Key SITC 2025 Data CancerNetwork

Published: Nov. 16, 2025, 5:11 p.m.
FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma - Targeted Oncology

FDA Clears New CDx for Pembrolizumab/Lenvatinib in Endometrial Carcinoma Targeted Oncology

Published: Nov. 12, 2025, 7:08 p.m.
Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet? - ts2.tech

Acrivon Therapeutics (ACRV): Precision Oncology Game-Changer or Overhyped Biotech Bet? ts2.tech

Published: Nov. 3, 2025, 2:12 p.m.
Triple meeting 2025 – early efficacy signs for Quanta | ApexOnco - Clinical Trials news and analysis - Oncology Pipeline

Triple meeting 2025 – early efficacy signs for Quanta | ApexOnco - Clinical Trials news and analysis Oncology Pipeline

Published: Oct. 27, 2025, 3:49 p.m.
Frontline Strategy: Why You Must Use IO Upfront in Endometrial Cancer - Targeted Oncology

Frontline Strategy: Why You Must Use IO Upfront in Endometrial Cancer Targeted Oncology

Published: Oct. 22, 2025, 6:21 p.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!